JP4800570B2 - 徐放性医薬組成物 - Google Patents

徐放性医薬組成物 Download PDF

Info

Publication number
JP4800570B2
JP4800570B2 JP2003508341A JP2003508341A JP4800570B2 JP 4800570 B2 JP4800570 B2 JP 4800570B2 JP 2003508341 A JP2003508341 A JP 2003508341A JP 2003508341 A JP2003508341 A JP 2003508341A JP 4800570 B2 JP4800570 B2 JP 4800570B2
Authority
JP
Japan
Prior art keywords
sustained release
pharmaceutically active
active ingredient
implant
blood level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003508341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004530721A (ja
JP2004530721A5 (https=
Inventor
アール． マルティノッド，サージ
ブランドン，マルコム
Original Assignee
バーバック コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーバック コーポレイション filed Critical バーバック コーポレイション
Publication of JP2004530721A publication Critical patent/JP2004530721A/ja
Publication of JP2004530721A5 publication Critical patent/JP2004530721A5/ja
Application granted granted Critical
Publication of JP4800570B2 publication Critical patent/JP4800570B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003508341A 2001-06-29 2002-07-01 徐放性医薬組成物 Expired - Fee Related JP4800570B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR6025 2001-06-29
AUPR6025A AUPR602501A0 (en) 2001-06-29 2001-06-29 Sustained release pharmaceutical composition
PCT/AU2002/000865 WO2003002102A1 (en) 2001-06-29 2002-07-01 Sustained release pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2004530721A JP2004530721A (ja) 2004-10-07
JP2004530721A5 JP2004530721A5 (https=) 2005-12-22
JP4800570B2 true JP4800570B2 (ja) 2011-10-26

Family

ID=3829991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003508341A Expired - Fee Related JP4800570B2 (ja) 2001-06-29 2002-07-01 徐放性医薬組成物

Country Status (10)

Country Link
US (1) US20040241204A1 (https=)
EP (1) EP1411904A4 (https=)
JP (1) JP4800570B2 (https=)
CN (1) CN1731988A (https=)
AU (2) AUPR602501A0 (https=)
BR (1) BR0210631A (https=)
CA (1) CA2452030A1 (https=)
CO (1) CO5540373A2 (https=)
NZ (1) NZ529859A (https=)
WO (1) WO2003002102A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
CN1638747A (zh) * 2002-01-24 2005-07-13 斯玛特药物系统公司 持续释放药物组合物
CN101683317A (zh) * 2004-05-31 2010-03-31 斯玛特药物系统公司 缓释组合物
JP2008502605A (ja) * 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
AU2005253646B2 (en) * 2004-06-16 2011-09-15 Virbac Corporation Sustained release vaccine composition
PT1781264E (pt) 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
EP1859788A1 (en) * 2006-05-24 2007-11-28 Abbott GmbH & Co. KG Production of enveloped pharmaceutical dosage forms
NZ552290A (en) * 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
BRPI0705822A2 (pt) * 2007-10-25 2009-06-23 Schering Plough Saude Animal Ltda formulação injetável com ação prolongada e uso de um agente semi-sintético derivado do grupo das avermectinas, em combinação com um polìmero biodegradável
ES2718612T3 (es) 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
EP2352544A4 (en) * 2008-11-07 2013-12-25 Combinent Biomedical Systems Inc DEVICES AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF DISEASES
CA2755753A1 (en) 2009-03-17 2010-09-23 Intervet International B.V. Macrocyclic lactone drug delivery system
KR101957625B1 (ko) * 2010-06-01 2019-03-12 백스터 인터내셔널 인코포레이티드 건조 및 안정한 지혈 조성물의 제조 방법
PT2598151T (pt) 2010-07-30 2019-04-15 Ceva Sante Animale Sa Composições para o tratamento da infestação por vermes do coração
JP5696279B2 (ja) * 2010-12-01 2015-04-08 学校法人自治医科大学 長期徐放型薬剤硬膜外腔留置システム
BR112014013371B1 (pt) 2011-12-02 2020-04-07 Merial Ltd formulações de moxidectina injetável de ação prolongada e novas formas de cristal de moxidectina
US20130190839A1 (en) * 2012-01-20 2013-07-25 Jane Rapsey Drug delivery using a sacrificial host
WO2014160026A2 (en) * 2013-03-14 2014-10-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
AU2013209343B1 (en) * 2013-05-14 2014-04-24 Activesignal Holding Limited Device for the Treatment of Bone Conditions
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
ITUB20153652A1 (it) 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
CN118680883A (zh) * 2018-06-25 2024-09-24 瑞艾克斯制药公司 用作植入物的可负载多孔结构
US20220152044A1 (en) * 2019-03-14 2022-05-19 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system
CN110559431B (zh) * 2019-10-11 2023-02-28 南京农业大学 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用
EP4477215A3 (en) 2020-12-08 2025-02-19 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals
US20240238226A1 (en) * 2021-03-09 2024-07-18 Adnan I. Qureshi Implantable sustained release device and a method of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4723958A (en) * 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
DK0463061T3 (da) * 1989-03-17 1993-07-12 Pitman Moore Inc Controlled-release tilførselsindretning til afgivelse af makromolekylære proteiner
FI916066A0 (fi) * 1989-06-21 1991-12-20 Univ Brown Res Found Neurologiskt vaordsystem.
FR2653338B1 (fr) * 1989-10-23 1994-06-10 Dow Corning Sa Formulation pour des pansements a liberation prolongee de medicament et son utilisation.
AU660290B2 (en) * 1990-08-09 1995-06-22 Endocon, Inc. Multiple drug delivery system
NZ239370A (en) * 1990-08-22 1994-04-27 Merck & Co Inc Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
JPH06321803A (ja) * 1993-05-17 1994-11-22 Kirin Brewery Co Ltd 水溶性ペプチドホルモンの徐放性製剤
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
FR2745180B1 (fr) * 1996-02-23 1998-05-07 Dow Corning Sa Procede de fabrication de dispositifs a liberation controlee
BR9812385A (pt) * 1997-09-23 2000-09-12 Pfizer Formulações parasiticidas
AUPP279698A0 (en) * 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
AU752225B2 (en) * 1998-07-17 2002-09-12 Pacira Pharmaceuticals, Inc. Biodegradable compositions for the controlled release of encapsulated substances
GB9816132D0 (en) * 1998-07-24 1998-09-23 Norbrook Lab Ltd Non-aqueous anthelmintic composition
AU5532699A (en) * 1998-09-05 2000-03-27 Seung Jin Lee Biodegradable particulate polymeric preparation and process for producing thereof
US6645192B2 (en) * 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
CN1378445B (zh) * 1999-08-06 2013-02-06 得克萨斯系统大学评议会 药物释放生物可降解纤维植入物
TW524696B (en) * 1999-11-10 2003-03-21 Sumitomo Pharma Sustained-release drug formulations
AU1556000A (en) * 1999-11-22 2001-06-04 Akzo Nobel N.V. Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
US20020131988A1 (en) * 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix

Also Published As

Publication number Publication date
JP2004530721A (ja) 2004-10-07
WO2003002102A1 (en) 2003-01-09
US20040241204A1 (en) 2004-12-02
CA2452030A1 (en) 2003-01-09
AUPR602501A0 (en) 2001-07-26
NZ529859A (en) 2005-11-25
CN1731988A (zh) 2006-02-08
EP1411904A1 (en) 2004-04-28
EP1411904A4 (en) 2006-06-07
AU2002344685B2 (en) 2008-05-15
BR0210631A (pt) 2004-07-27
CO5540373A2 (es) 2005-07-29

Similar Documents

Publication Publication Date Title
JP4800570B2 (ja) 徐放性医薬組成物
JP4913321B2 (ja) 徐放性医薬組成物
AU2002344685A1 (en) Sustained release pharmaceutical composition
JP2005505557A (ja) 持続放出医薬組成物の調製
AU2002344686A1 (en) Sustained release delivery system
JP2013049705A (ja) 持続放出医薬組成物
US20050063907A1 (en) Radioopaque sustained release pharmaceutical system
AU2002344687B2 (en) Treatment of parasitic disease
AU2002344687A1 (en) Treatment of parasitic disease
MXPA02004711A (es) Formulaciones de farmaco de liberacion sostenida para implantacion.
AU2002315568B2 (en) Preparation of sustained release pharmaceutical composition
AU2002366248A1 (en) Radioopaque sustained release pharmaceutical system
AU2002315568A1 (en) Preparation of sustained release pharmaceutical composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050609

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20081212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110804

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140812

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees